cosibelimab

Home
Ligands
cosibelimab

GtoPdb Ligand ID: 13676

Synonyms: CK-301 | CK301 | cosibelimab-ipdl | Unloxcyt®

cosibelimab is an approved drug (FDA (2024))

Comment: Cosibelimab (CK-301) is a human anti-programmed cell death 1 ligand 1 (PD-L1) monoclonal antibody. It belongs to the immune checkpoint inhibitor class of anti-tumour drugs. Cosibelimab blocks inhibitory PD-L1 regulation of the anti-tumour immune response and induces antibody-dependent cell-mediated cytotoxicity (ADCC).
Peptide sequence alignments indicate identity between peptide sequences for the INN cosibelimab and those for antibody CTI-48 as claimed in patent US10590199B2 [1].

References
1. Belk J, Sharkey NJ, Gorelik L. (2020) PD-L1-specific antibodies and methods of using the same. Patent number: US10590199B2. Assignee: Adimab LLC, Fortress Biotech Inc., Checkpoint Therapeutics Inc. Priority date: 28/06/2017. Publication date: 17/03/2020.
2. Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR et al.. (2023) Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer, 11 (10). [PMID:37848259]

References

1. Belk J, Sharkey NJ, Gorelik L. (2020)
PD-L1-specific antibodies and methods of using the same.
Patent number: US10590199B2. Assignee: Adimab LLC, Fortress Biotech Inc., Checkpoint Therapeutics Inc. Priority date: 28/06/2017. Publication date: 17/03/2020.

2. Clingan P, Ladwa R, Brungs D, Harris DL, McGrath M, Arnold S, Coward J, Fourie S, Kurochkin A, Malan DR et al.. (2023)
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma.
J Immunother Cancer, 11 (10). [PMID:37848259]